CD274 and triple-negative breast carcinoma: Suppression of PD-L1 by BET inhibition was evident in the context of 9p24.1-amplified Hodgkin lymphoma, where PD-L1 is constitutively expressed [12], as well as triple-negative breast cancer (TNBC) as a model of IFNγ-dependent expression.